A detailed history of Yousif Capital Management, LLC transactions in Incyte Corp stock. As of the latest transaction made, Yousif Capital Management, LLC holds 18,041 shares of INCY stock, worth $1.29 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
18,041
Previous 21,254 15.12%
Holding current value
$1.29 Million
Previous $1.29 Million 7.45%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

SELL
$57.33 - $68.61 $184,201 - $220,443
-3,213 Reduced 15.12%
18,041 $1.19 Million
Q2 2024

Jul 31, 2024

SELL
$51.18 - $63.75 $34,802 - $43,350
-680 Reduced 3.1%
21,254 $1.29 Million
Q1 2024

Apr 26, 2024

SELL
$56.55 - $66.59 $21,545 - $25,370
-381 Reduced 1.71%
21,934 $1.25 Million
Q4 2023

Feb 01, 2024

SELL
$52.16 - $64.19 $1.07 Million - $1.32 Million
-20,556 Reduced 47.95%
22,315 $1.4 Million
Q3 2023

Oct 30, 2023

SELL
$57.77 - $65.93 $62,795 - $71,665
-1,087 Reduced 2.47%
42,871 $2.48 Million
Q2 2023

Aug 02, 2023

BUY
$60.95 - $75.51 $360,580 - $446,717
5,916 Added 15.55%
43,958 $2.74 Million
Q1 2023

May 02, 2023

BUY
$70.23 - $86.01 $294,966 - $361,242
4,200 Added 12.41%
38,042 $2.75 Million
Q4 2022

Jan 09, 2023

BUY
$67.18 - $84.11 $526,086 - $658,665
7,831 Added 30.11%
33,842 $0
Q3 2022

Nov 04, 2022

SELL
$66.18 - $82.86 $37,126 - $46,484
-561 Reduced 2.11%
26,011 $1.73 Million
Q2 2022

Aug 01, 2022

SELL
$66.18 - $83.18 $104,233 - $131,008
-1,575 Reduced 5.6%
26,572 $2.02 Million
Q1 2022

May 12, 2022

SELL
$66.02 - $79.71 $27,266 - $32,920
-413 Reduced 1.45%
28,147 $2.24 Million
Q4 2021

Jan 31, 2022

BUY
$63.34 - $74.11 $1.81 Million - $2.12 Million
28,560 New
28,560 $2.1 Million

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $16B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Yousif Capital Management, LLC Portfolio

Follow Yousif Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Yousif Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Yousif Capital Management, LLC with notifications on news.